MET and non-small cell lung carcinoma: When tested in a phase 1 study in 38 EGFR-mutated lung cancer patients who progressed on osimertinib treatment, the combination of telisotuzumab vedotin and osimertinib showed a median PFS of 7.4 months and an ORR of 50%, associated with a manageable safety profile [151], thus representing a potential additional tool for overcoming MET-mediated osimertinib resistance in EGFR-mutated NSCLC.